Chemed Corporation (CHE) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
CHE Revenue Growth
Revenue Breakdown (FY 2025)
CHE's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
CHE Revenue Analysis (2014–2025)
As of May 8, 2026, Chemed Corporation (CHE) generated trailing twelve-month (TTM) revenue of $2.54 billion, reflecting modest growth of +1.6% year-over-year. The most recent quarter (Q1 2026) recorded $657.5 million in revenue, up 2.8% sequentially.
Looking at the longer-term picture, CHE's 5-year compound annual growth rate (CAGR) stands at +4.0%, indicating moderate growth over time. The company achieved its highest annual revenue of $2.53 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows CHE's business is primarily driven by Segment Vitas (64%), and Segment Roto Rooter (36%). With over half of revenue concentrated in Segment Vitas, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ADUS (+19.6% YoY), ENSG (+19.2% YoY), and SCI (+2.8% YoY), CHE has underperformed the peer group in terms of revenue growth. Compare CHE vs ADUS →
CHE Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CHECurrent | $2.5B | +1.6% | +4.0% | 13.4% | |
 ADUS | $1.4B | +19.6% | +13.2% | 9.7% | |
 ENSG | $5.1B | +19.2% | +16.1% | 8.6% | |
 SCI | $4.3B | +2.8% | +4.2% | 22.6% | |
 CSV | $417M | +2.1% | +4.8% | 23.7% | |
 HCSG | $1.8B | +7.1% | +0.9% | 2.6% |
CHE Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $2.53B | +4.1% | $758.3M | 30.0% | $338.2M | 13.4% |
| 2024 | $2.43B | +7.4% | $854.3M | 35.1% | $366.5M | 15.1% |
| 2023 | $2.26B | +6.1% | $798.8M | 35.3% | $340.6M | 15.0% |
| 2022 | $2.13B | -0.2% | $765.1M | 35.8% | $343.5M | 16.1% |
| 2021 | $2.14B | +2.9% | $769.8M | 36.0% | $343.0M | 16.0% |
| 2020 | $2.08B | +7.3% | $701.4M | 33.7% | $389.7M | 18.7% |
| 2019 | $1.94B | +8.7% | $617.4M | 31.9% | $257.4M | 13.3% |
| 2018 | $1.78B | +7.0% | $555.0M | 31.1% | $243.6M | 13.7% |
| 2017 | $1.67B | +5.7% | $516.2M | 31.0% | $113.0M | 6.8% |
| 2016 | $1.58B | +2.2% | $461.4M | 29.3% | $178.7M | 11.3% |
See CHE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CHE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CHE vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCHE — Frequently Asked Questions
Quick answers to the most common questions about buying CHE stock.
Is CHE's revenue growth accelerating or slowing?
CHE revenue growth slowed to +1.6%, below the 5-year CAGR of +4.0%. TTM revenue is $2.5B. The deceleration marks a shift from historical growth rates.
What is CHE's long-term revenue growth rate?
Chemed Corporation's 5-year revenue CAGR of +4.0% reflects the variable expansion pattern. Current YoY growth of +1.6% is near this long-term average.
How is CHE's revenue distributed by segment?
CHE reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.